Stocks · News reference
Intensity Therapeutics reported that 71% of patients in the first cohort of its INVINCIBLE-4 study achieved a pathological complete response following treatment with INT230-6.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Gainers Veeva Systems (NYSE:VEEV) shares increased by 8.7% to $266.15 during Wednesday's after-market session. The market value of their outstanding shares is at $40.0 billion. The company's, Q2 earnings came
Intensity Therapeutics (NASDAQ:INTS) reported quarterly losses of $(1.11) per share which met the analyst consensus estimate. This is a 66.96 percent increase over losses of $(3.36) per share from the same period last